Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
Hypertension 2008
Fixed-dose Combination Treatment in Hypertension: Updating the Guidelines
Berlin, Germany / June 14-19, 2008
Berlin - Two recently reported trials have had profound implications for blood pressure (BP) management guidelines. ADVANCE was the first clinical trial to demonstrate the benefits of BP reduction on microvascular and macrovascular events...
68th Scientific Sessions of the American Diabetes Association
Anti-diabetes Therapy Acting on the Incretin System Associated with Improvement in ß-cell Function
San Francisco, California / June 6-10, 2008
San Francisco - In a series of recent studies on type 2 diabetes, it was suggested that treatment to improve incretin effect should be initiated early with the intention of slowing the disease process. Unlike sulfonylureas, which stimulate...
68th Scientific Sessions of the American Diabetes Association
ADVANCE: Intensive Glucose Control Demonstrates Reduction in Vascular Events in Patients with Type 2 Diabetes
San Francisco, California / June 6-10, 2008
San Francisco - Fulfilling expectations, intensive glucose lowering has now been shown to significantly reduce the risk of microvascular and macrovascular events in patients with type 2 diabetes (DM2). In the largest study ever undertaken...
JOURNAL CLUB
The Significance of LDL for Clinical Benefit in the Context of Results from the ENHANCE Study
May 2008
Editorial Overview: Daniel Gaudet, MD, PhD Professor of Medicine Université de Montréal Montreal, Quebec The recently published ENHANCE study defied expectations. The trial was conducted in patients with familial hypercholesterolemia, a...
Based on presentations from the Primary Care Today Educational Conference and Medical Exposition
Optimal Risk Reduction in Diffuse Vascular Disease: Focus on Peripheral Arterial Disease
Toronto, Ontario / May 8-10, 2008
INTRODUCTION Atherothrombosis can occur in the coronary, cerebral and peripheral arterial beds. The disease that is the leading cause of death worldwide is better characterized as diffuse vascular disease, as patients with symptomatic...
MEDICAL FRONTIERS - 16th Scientific Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine
Improving Diagnosis and Safety: An Inside View of Recent Advances and Safety Developments in High-resolution Vascular and Cardiac MRI
Toronto, Ontario / May 3-9, 2008
Figure 1. In recent years, magnetic resonance angiography (MRA) has become a reliable diagnostic tool used in a variety of indications, including imaging of cerebral, thoracic, abdominal, renal and peripheral arteries. Several different...
JOURNAL CLUB Based on the ONTARGET trial published in: N Engl J Med 2008 Apr 10;358(15):1547-59 and Presentations during the 57th Annual Scientific Sessions of the American College of Cardiology
Clinical Trial Update: Putting New Findings in Perspective
Chicago, Illinois / March 29-April 1, 2008
BASED ON INTERVIEWS WITH: Ellen D. Burgess, MD, FACP, FRCPC Professor, Department of Medicine Director, Hypertension Research Clinic University of Calgary Foothills Hospital Calgary, Alberta Pierre Larochelle, MD, PhD, FRCPC Director,...
57th Annual Scientific Sessions of the American College of Cardiology
Re-evaluating Stents: Objective Data from Large Patient Registries
Chicago, Illinois / March 29-April 1, 2008
Chicago - New data presented this week as well as a new meta-analysis continue to suggest that drug-eluting stents (DES) are superior to bare metal stents (BMS) for long-term outcomes in most settings. At the annual scientific sessions of...
Based on presentations from the 57th Scientific Session of the American College of Cardiology
ONTARGET: A Landmark Trial with Immediate Clinical Implications
Chicago, Illinois / March 29-April 1, 2008
INTRODUCTION The ONTARGET (Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) study has demonstrated that 80 mg of the angiotensin-receptor blocker (ARB) telmisartan is as effective as 10 mg of the ACE...